Litigation Details for In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)
✉ Email this page to a colleague
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-08-04 |
| Court | District Court, D. Kansas | Date Terminated | 2022-07-11 |
| Cause | 28:1407 Multi-District Litigation | Assigned To | Daniel Dale Crabtree |
| Jury Demand | Both | Referred To | Teresa James |
| Patents | 7,449,012; 7,794,432; 8,048,035; 8,870,827 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-01-22 | 123 | Response to Motion | subsidiaries, sued Teva for infringing U.S. Patent No. 7,449,012. The claim was amended in November…monopoly resulting from a drug patent; indeed, Defendants have patents only on one of many possible delivery… With their additional patents in place—one of which, U.S. Patent No. 7,794,432, having been sought…stressing that Mylan was adding yet another patent to the already-patented EpiPen device in order to “put in…Intelliject’s e-cue infringed the ‘432 patent, despite that the ‘432 patent was not obtained until September | External link to document |
| 2019-08-22 | 1848 | Memorandum in Support of Motion | EpiPen patents, U.S. Patent Nos. 7,449,012 (the “’012 Patent”) and 7,794,432 (the “’432 Patent”).2 Prior…opines on the validity of the ’432 patent, but fails to apply accepted patent validity legal principles. Indeed… history to conclude that “the patent claims of the ’432 patent [were] quite weak, … the ’432 patent after the KSR decision. Thus, the PTO agreed the invention was patentable even under… Analyzing Patent Validity Professor Torrance posits that the ’432 patent is “quite weak | External link to document |
| 2020-02-27 | 2018 | Memorandum & Order - Unsealed Copy | sued Teva for infringing U.S. Patent No. 7,449,012 (“the Teva patent litigation”). In November 2010,… Patent Infringement Lawsuits The Pfizer defendants own the patents protecting the…that end, defendants allegedly added patents to the already-patented EpiPen to stop generic competitors.…secured ’432 patent. Later, King and Meridian dropped their claims based on the ’012 patent, leaving only…claims for the ’432 patent. On April 27, 2012, the parties settled the Teva patent litigation. According | External link to document |
| 2020-07-20 | 2170 | Motion to Strike | U.S. Patent No. 8,048,035 (“’035 Patent”), was issued by the USPTO in November 2011. These …two additional EpiPen patents were awaiting approval by the U.S. Patent and Trademark Office …application for what would become U.S. Patent No. 8,870,827 (the “’827 Patent”) was made publicly available… ’827 Patent was issued by the USPTO in October 2014.186 Another EpiPen-related patent, U.S.… patents differ from prior patents held by Pfizer on EpiPen Auto-Injector and more specifically | External link to document |
| 2021-05-24 | 2353 | Exhibit List | re EpiCard 649 2008.11.11 US Pat 7,449,012 650 2009.01.01 Patent Case Mgmt Judicial Guide Excerpts…Presentation 665 2020.06.25 Patent Examining Manual - 2142 666 2020.06.25 Patent Examining Manual - 2145…Krauss Email to Clarke 356 UNDATED. Report on Patent Expiration and Counter- 357 UNDATED. Pfizer Presentation | External link to document |
| 2021-06-23 | 2381 | Order on Motion for Summary Judgment | 8,048,035 (“’035 Patent”). Doc. 2146-2 at 4 (Defs.’ Ex. 135). The disputes at issue in the Teva litigation…additional Pfizer EpiPen patent: U.S. Patent No. 7,794,432B2 (the “’432 Patent”). First Amended Complaint… ’827 Patent. Id. In November 2011, the USPTO issued another EpiPen-related patent, U.S. Patent No. 8,048,035…the ’035 Patent not at issue in the litigation, and any future patents like the ’827 Patent). Doc. 2146…Neither one of the other two patents—the ’827 Patent nor the ’035 Patent—was in dispute in the Teva/EpiPen | External link to document |
| 2017-10-17 | 60 | Amended Complaint | 8, 2009) alleging infringement of U.S. Patent No. 7,449,012. King filed a First Amended Complaint on…equivalents, and any patents that purportedly protect each drug. 113. Drug patents typically last…ordinary patent term of twenty years, often compensate for unfairness in the ordinary patent process …not infringe any patents claiming to cover the reference product because: (1) no patents are listed in …drug until all applicable patents have expired; or (4) all applicable patents are invalid or will not | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
